A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults (CaboCombo)
A Prospective Observational International Study of Cabozantinib Tablets in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma in Adults
Sponsor: Ipsen
Listed as NCT05361434, this observational or N/A phase trial focuses on Advanced Renal Cell Carcinoma and remains ongoing. Sponsored by Ipsen, it has been updated 36 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
36 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
-
Feb 2026 — May 2026 [monthly]
Active Not Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting
-
Oct 2025 — Jan 2026 [monthly]
Active Not Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting
▶ Show 31 earlier versions
-
Jul 2025 — Sep 2025 [monthly]
Active Not Recruiting
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting
-
Mar 2025 — May 2025 [monthly]
Active Not Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting
-
Oct 2024 — Dec 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
-
May 2024 — Jul 2024 [monthly]
Recruiting
-
Apr 2024 — May 2024 [monthly]
Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Recruiting
-
Feb 2024 — Mar 2024 [monthly]
Recruiting
-
Jan 2024 — Feb 2024 [monthly]
Recruiting
-
Nov 2023 — Jan 2024 [monthly]
Recruiting
-
Oct 2023 — Nov 2023 [monthly]
Recruiting
-
Sep 2023 — Oct 2023 [monthly]
Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Recruiting
-
Jul 2023 — Aug 2023 [monthly]
Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Recruiting
-
May 2023 — Jun 2023 [monthly]
Recruiting
-
Apr 2023 — May 2023 [monthly]
Recruiting
-
Jan 2023 — Apr 2023 [monthly]
Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Recruiting
-
Nov 2022 — Dec 2022 [monthly]
Recruiting
-
Oct 2022 — Nov 2022 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Oct 2022 [monthly]
Not Yet Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Not Yet Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
The purpose of this study is to collect data to describe the safety and effectiveness of cabozantinib and nivolumab in combination as a first-line treatment in adults with aRCC with clear cell-component, according to real-world clinical practice. The decision to prescribe cabozantinib and nivolumab in combination will be made prior to, and independently from, the decision to enrol the participant in study.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Ars-Laquenexy, France , Athens, Greece , Athens, Greece , Avignon, France , Belfast, United Kingdom , Besançon, France , Bezannes, France , Bordeaux, France , Bordeaux, France and 56 more locations